Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Muñoz-Couselo

Showing results (51-60 of 79) with videos related to

Pageof 8
Sort By:
Journal for Immunotherapy of Cancer|October 17, 2023
Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinomaPhilip Clingan, Rahul Ladwa, Daniel Brungs, et al.
Nature Communications|December 2, 2021
Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trialMaria Gonzalez-Cao, Clara Mayo de Las Casas, Juana Oramas, et al.
Frontiers in Oncology|March 13, 2025
Real-life evidence of encorafenib plus binimetinib in patients with unresectable advanced or metastatic BRAF<sup>V600</sup>-mutant melanoma in Spain: the BECARE (GEM-2002) trialAinara Soria, Pedro Sanchez Mauriño, Juan José Serrano Domingo, et al.
European Journal of Cancer (Oxford, England : 1990)|August 13, 2021
Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trialsIgnacio Matos, Guillermo Villacampa, Cinta Hierro, et al.
Journal of the American Academy of Dermatology|October 7, 2025
Efficacy and safety of cosibelimab in advanced cutaneous squamous cell carcinoma: Results from a Pivotal Open-label Study with a median follow-up of ≥2 yearsEmily S Ruiz, Eva Muñoz-Couselo, Henri Montaudié, et al.
Cancer Research|May 18, 2022
Activity and Resistance of a Brain-Permeable Paradox Breaker BRAF Inhibitor in Melanoma Brain MetastasisEster Bonfill-Teixidor, Raffaella Iurlaro, Cornelia Handl, et al.
European Journal of Cancer (Oxford, England : 1990)|August 25, 2019
Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)Paul Nathan, Paolo A Ascierto, John Haanen, et al.
European Journal of Cancer (Oxford, England : 1990)|October 4, 2019
Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172)Dirk Schadendorf, Paolo A Ascierto, John Haanen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2023
Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial ResultsAdi Diab, Helen Gogas, Shahneen Sandhu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 22, 2023
Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in <i>NRAS</i>-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label StudyFilippo de Braud, Christophe Dooms, Rebecca S Heist, et al.
Pageof 8

Showing results (51-60 of 79) with videos related to

Sort By:
Pageof 8
Journal for Immunotherapy of Cancer|October 17, 2023
Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinomaPhilip Clingan, Rahul Ladwa, Daniel Brungs, et al.
Nature Communications|December 2, 2021
Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trialMaria Gonzalez-Cao, Clara Mayo de Las Casas, Juana Oramas, et al.
Frontiers in Oncology|March 13, 2025
Real-life evidence of encorafenib plus binimetinib in patients with unresectable advanced or metastatic BRAF<sup>V600</sup>-mutant melanoma in Spain: the BECARE (GEM-2002) trialAinara Soria, Pedro Sanchez Mauriño, Juan José Serrano Domingo, et al.
European Journal of Cancer (Oxford, England : 1990)|August 13, 2021
Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trialsIgnacio Matos, Guillermo Villacampa, Cinta Hierro, et al.
Journal of the American Academy of Dermatology|October 7, 2025
Efficacy and safety of cosibelimab in advanced cutaneous squamous cell carcinoma: Results from a Pivotal Open-label Study with a median follow-up of ≥2 yearsEmily S Ruiz, Eva Muñoz-Couselo, Henri Montaudié, et al.
Cancer Research|May 18, 2022
Activity and Resistance of a Brain-Permeable Paradox Breaker BRAF Inhibitor in Melanoma Brain MetastasisEster Bonfill-Teixidor, Raffaella Iurlaro, Cornelia Handl, et al.
European Journal of Cancer (Oxford, England : 1990)|August 25, 2019
Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)Paul Nathan, Paolo A Ascierto, John Haanen, et al.
European Journal of Cancer (Oxford, England : 1990)|October 4, 2019
Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172)Dirk Schadendorf, Paolo A Ascierto, John Haanen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 31, 2023
Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial ResultsAdi Diab, Helen Gogas, Shahneen Sandhu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 22, 2023
Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in <i>NRAS</i>-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label StudyFilippo de Braud, Christophe Dooms, Rebecca S Heist, et al.
Pageof 8